Nautilus Biotechnology (NASDAQ:NAUT) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Nautilus Biotechnology (NASDAQ:NAUT) issued its quarterly earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04, Zacks reports. During the same period in the previous year, the company posted ($0.13) earnings per share.

Nautilus Biotechnology Trading Down 4.3 %

NAUT stock opened at $2.65 on Thursday. The firm has a 50 day simple moving average of $2.75 and a 200-day simple moving average of $2.62. The company has a market capitalization of $332.34 million, a P/E ratio of -4.73 and a beta of 1.22. Nautilus Biotechnology has a twelve month low of $2.19 and a twelve month high of $3.45.

Insider Activity at Nautilus Biotechnology

In other Nautilus Biotechnology news, VP Mary E. Godwin sold 47,031 shares of the firm’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $2.87, for a total transaction of $134,978.97. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 40.50% of the stock is currently owned by corporate insiders.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.